WO2026139906 - HUMANIZED ANTI-MESOTHELIN SCFVS
National phase entry is expected:
Publication Number
WO/2026/139906
Publication Date
02.07.2026
International Application No.
PCT/IB2025/063421
International Filing Date
23.12.2025
Title **
[English]
HUMANIZED ANTI-MESOTHELIN SCFVS
[French]
SCFV ANTI-MÉSOTHÉLINE HUMANISÉS
Applicants **
UNIVERSITY HEALTH NETWORK
Inventors
HIRANO, Naoto
OHASHI, Yota
LY, Dalam
SASO, Kayoko
MATSUNAGA, Yukiko
BURT, Brian
Priority Data
63/738,245
23.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5553 | |
| EPO | Filing, Examination, Granting | 104133 | |
| Japan | Filing, Examination, Granting | 4981 | |
| South Korea | Filing, Examination, Granting | 8335 | |
| USA | Filing, Examination, Granting | 25190 |
Total:
148,192
Contact Us
Abstract[English]
The disclosure provides scFv molecule that specifically bind mesothelin, chimeric antigen receptors that comprise antigen-binding domains comprising the scFv, nucleotides that encode the same, cells comprising the same, and methods of using the same in the treatment of cancer.[French]
La divulgation fournit des molécules scFv se liant spécifiquement à la mésothéline, des récepteurs antigéniques chimériques comprenant des domaines de liaison à l'antigène comprenant les scFv, des nucléotides codant pour ceux-ci, des cellules comprenant ceux-ci, et des méthodes d'utilisation de ceux-ci dans le traitement du cancer.